$125 | Single User
$250 | Site License
$375 | Global License

GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) - Financial and Strategic SWOT Analysis Review
[Report Updated: 31-07-2018]

Published by Global Data: 31 Jul 2018 | 216360 | In Stock
Related Topics: GlaxoSmithKline

Introduction

GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.

- Corporate strategy – Analyst’s summarization of the company’s business strategy.

- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.

- Company history – Progression of key events associated with the company.

- Major products and services – A list of major products, services and brands of the company.

- Key competitors – A list of key competitors to the company.

- Key employees – A list of the key executives of the company.

- Executive biographies – A brief summary of the executives’ employment history.

- Key operational heads – A list of personnel heading key departments/functions.

- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities – A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

GlaxoSmithKline Pharmaceuticals Ltd (GSK India), a subsidiary of GlaxoSmithKline Plc manufactures and markets prescription medicines and vaccines. The prescription medicines includes therapeutic areas such as, analgesic, anti-infective, anti-inflammatory, anti-parasitic, cardiovascular, dermatology, diabetes, endocrine, gastrointestinal, gynaecology, immunosupressants, nutritional, respiratory, central nervous system (CNS) and oncology. The company offers a range of vaccines for the prevention of hepatitis A, hepatitis B, influenzae, diphtheria, tetanus, pertussis, rotavirus, tetanus toxoid, reduced diphtheria toxoid, human papillomavirus vaccine and others. GSK India is headquartered in Mumbai, Maharashtra, India.

GlaxoSmithKline Pharmaceuticals Ltd Key Recent Developments

May 24,2018: GlaxoSmithKline Pharmaceuticals delivers strong Q4 performance with Revenue of 749 Cr and PBT before exceptionals growing 14%

Mar 16,2018: GlaxoSmithKline Pharmaceuticals: Change in Directorate

Feb 26,2018: Champion Baseball Pitcher Justin Verlander Teams Up with FLONASE Allergy Relief for a Homerun Allergy Season

Feb 07,2018: GlaxoSmithKline: Full year and fourth quarter 2017

Feb 02,2018: GlaxoSmithKline Pharmaceuticals delivers strong Q3 performance with Revenue of 704 Cr.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents
for GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) - Financial and Strategic SWOT Analysis Review [Report Updated: 31-07-2018]

  • Table of Contents

    Table of Contents 3

    List of Tables 5

    List of Figures 5

    Section 1 - About the Company 6

    GlaxoSmithKline Pharmaceuticals Ltd - Key Facts 6

    GlaxoSmithKline Pharmaceuticals Ltd - Key Employees 7

    GlaxoSmithKline Pharmaceuticals Ltd - Key Employee Biographies 8

    GlaxoSmithKline Pharmaceuticals Ltd - Key Operational Employees 9

    GlaxoSmithKline Pharmaceuticals Ltd - Major Products and Services 10

    GlaxoSmithKline Pharmaceuticals Ltd - History 16

    GlaxoSmithKline Pharmaceuticals Ltd - Locations And Subsidiaries 18

    Head Office 18

    Other Locations & Subsidiaries 18

    Joint Venture 18

    Section 2 – Company Analysis 19

    Company Overview 19

    GlaxoSmithKline Pharmaceuticals Ltd - Business Description 20

    GlaxoSmithKline Pharmaceuticals Ltd - Corporate Strategy 21

    GlaxoSmithKline Pharmaceuticals Ltd - SWOT Analysis 22

    SWOT Analysis - Overview 22

    GlaxoSmithKline Pharmaceuticals Ltd - Strengths 22

    GlaxoSmithKline Pharmaceuticals Ltd - Weaknesses 23

    GlaxoSmithKline Pharmaceuticals Ltd - Opportunities 24

    GlaxoSmithKline Pharmaceuticals Ltd - Threats 25

    GlaxoSmithKline Pharmaceuticals Ltd - Key Competitors 26

    Section 3 – Company Financial Ratios 27

    Financial Ratios - Capital Market Ratios 27

    Financial Ratios - Annual Ratios 28

    Performance Chart 31

    Financial Performance 31

    Financial Ratios - Ratio Charts 32

    Section 4 – Company’s Lifesciences Financial Deals and Alliances 33

    GlaxoSmithKline Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 33

    GlaxoSmithKline Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 34

    GlaxoSmithKline Pharmaceuticals Ltd, Recent Deals Summary 35

    Section 5 – Company’s Recent Developments 36

    May 24, 2018: GlaxoSmithKline Pharmaceuticals delivers strong Q4 performance with Revenue of 749 Cr and PBT before exceptionals growing 14% 36

    Mar 16, 2018: GlaxoSmithKline Pharmaceuticals: Change in Directorate 37

    Feb 07, 2018: GlaxoSmithKline: Full year and fourth quarter 2017 38

    Feb 02, 2018: GlaxoSmithKline Pharmaceuticals delivers strong Q3 performance with Revenue of 704 Cr. 64

    Oct 25, 2017: GlaxoSmithKline Pharmaceuticals India records a Revenue increase of 5% 65

    Oct 25, 2017: GlaxoSmithKline Pharmaceuticals Appointment of Ms. Puja Thakur as Whole-time Director and Chief Financial officer 66

    Jul 25, 2017: GlaxoSmithKline Pharmaceuticals QI performance temporarily impacted by GST trade channel destocking whilst fundamentals remain intact 67

    May 19, 2017: GlaxoSmithKline Pharmaceuticals records 11% Sales growth for Q4, FY 2016-17 68

    Feb 11, 2017: GlaxoSmithKline Pharmaceuticals announces executive director change 69

    Section 6 – Appendix 70

    Methodology 70

    Ratio Definitions 70

    About GlobalData 74

    Contact Us 74

    Disclaimer 74

List Of Tables
in GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) - Financial and Strategic SWOT Analysis Review [Report Updated: 31-07-2018]

List of Tables

GlaxoSmithKline Pharmaceuticals Ltd, Key Facts 6

GlaxoSmithKline Pharmaceuticals Ltd, Key Employees 7

GlaxoSmithKline Pharmaceuticals Ltd, Key Employee Biographies 8

GlaxoSmithKline Pharmaceuticals Ltd, Key Operational Employees 9

GlaxoSmithKline Pharmaceuticals Ltd, Major Products and Services 10

GlaxoSmithKline Pharmaceuticals Ltd, History 16

GlaxoSmithKline Pharmaceuticals Ltd, Joint Venture 18

GlaxoSmithKline Pharmaceuticals Ltd, Key Competitors 26

GlaxoSmithKline Pharmaceuticals Ltd, Ratios based on current share price 27

GlaxoSmithKline Pharmaceuticals Ltd, Annual Ratios 28

GlaxoSmithKline Pharmaceuticals Ltd, Annual Ratios (Cont...1) 29

GlaxoSmithKline Pharmaceuticals Ltd, Annual Ratios (Cont...2) 30

GlaxoSmithKline Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 33

GlaxoSmithKline Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 34

GlaxoSmithKline Pharmaceuticals Ltd, Recent Deals Summary 35

Currency Codes 70

Capital Market Ratios 70

Equity Ratios 71

Profitability Ratios 71

Cost Ratios 72

Liquidity Ratios 72

Leverage Ratios 73

Efficiency Ratios 73

List Of Figures, Charts and Diagrams
in GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) - Financial and Strategic SWOT Analysis Review [Report Updated: 31-07-2018]

List of Figures

GlaxoSmithKline Pharmaceuticals Ltd, Performance Chart (2015 - 2018) 31

GlaxoSmithKline Pharmaceuticals Ltd, Ratio Charts 32

GlaxoSmithKline Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 33

GlaxoSmithKline Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 34

Additional Details

Publisher

Global Data

Publisher Information

Reference

216360 | GDPH113643FSA

Number of Pages

74

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
GlaxoSmithKline Partnering Deals and Alliances 2010 to 2016
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering...
01 Oct 2016 by Current Partnering USD $1,495 More Info
GlaxoSmithKline K.K. - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryGlaxoSmithKline K.K. (GSK Japan) a subsidiary of GlaxoSmithKline Plc is a pharmaceutical comp...
10 Mar 2016 by Global Data USD $250 More Info
GlaxoSmithKline Pharmaceuticals Limited (GLAXO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryGlaxoSmithKline Pharmaceuticals Limited (GSK India) is a pharmaceutical company that manufact...
04 Mar 2016 by Global Data USD $250 More Info
GlaxoSmithKline Plc (GSK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryGlaxoSmithKline plc (GSK) is a healthcare company, which focuses on the development, manufact...
04 Mar 2016 by Global Data USD $250 More Info
GlaxoSmithKline Plc (GSK) - Medical Equipment - Deals and Alliances Profile
SummaryGlaxoSmithKline plc (GSK) is a healthcare company, which focuses on the development, manufact...
24 Feb 2016 by Global Data USD $250 More Info
GlaxoSmithKline Consumer Nigeria PLC (GLAXOSMITH) - Financial and Strategic SWOT Analysis Review
SummaryGlaxoSmithKline Consumer Nigeria PLC (GlaxoSmithKline Consumer Nigeria) a subsidiary of Glaxo...
09 Jan 2016 by Global Data USD $300 More Info
GlaxoSmithKline Consumer Nigeria PLC (GLAXOSMITH) - Financial and Strategic SWOT Analysis Review
SummaryGlaxoSmithKline Consumer Nigeria PLC (GlaxoSmithKline Consumer Nigeria) a subsidiary of Glaxo...
08 Nov 2015 by Global Data USD $300 More Info
Physician Views: Is GlaxoSmithKline's BRAF/MEK combo making headway in V600 mutation-positive melanoma patients?
Scope Although the clinical promise of cancer immunotherapies looks poised to see these products gai...
22 Jul 2014 by FirstWord Pharma USD $695 More Info
Physician Views: Assessing the launch of GlaxoSmithKline's Breo Ellipta
Scope It remains early in the launch, but available evidence suggests that GlaxoSmithKline's Breo El...
21 Jan 2014 by FirstWord Pharma USD $695 More Info
Physician Views: Can GlaxoSmithKline strike early with Anoro? / What role will dosing, inhaler type play in uptake of LAMA/LABA combinations for COPD?
ScopeThis year looks set to be one of notable evolution for the US chronic obstructive pulmonary dis...
01 Aug 2013 by FirstWord Pharma USD $695 More Info

This report is published by Global Data

Download Free Report Summary PDF

GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) - Financial and Strategic SWOT Analysis Review [Report Updated: 31-07-2018] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • 360i Research
  • 99Strategy
  • Allied Market Research
  • Asia Market Information & Development Co.
  • Azoth Analytics
  • BioInformant
  • Black Swan Analysis
  • Canadean
  • CBR Pharma Insights
  • CRI
  • Current Analysis
  • Current Partnering
  • Daedal Research
  • Data bridge
  • Delve Insight
  • DPI Research
  • FirstWord Pharma
  • Future Market Insights
  • GBI Research
  • Global Data
  • Global Markets Direct
  • Global Research and Data Services GRDS
  • GMR Data
  • HeyReport
  • HongChun
  • HTStec
  • ICD Research
  • iGATE Research
  • IMARC
  • Industry ARC
  • Inkwood Research
  • IQ4I
  • Jain PharmaBiotech
  • Kelly Scientific
  • La Merie
  • Lifescience Intellipedia
  • LP Information
  • Market Data Forecast
  • Market Research Future
  • Marketline
  • MarketsandMarkets
  • McDerson
  • MedMarket Diligence
  • Meticulous Research
  • MicroMarketMonitor
  • MIReports
  • Mordor Intelligence LLC
  • MP Advisors
  • Occams Business Research
  • Prof Research
  • Progressive Markets
  • ProGrow Pharma Partners
  • Renub
  • Research Impact
  • RNCOS
  • Rockville Research
  • S&P Consulting
  • StratisticsMRC
  • The Business Research Company
  • Triton Market Research
  • Venture Planning Group (VPG)